Intellectus Partners, LLC Affimed N.V. Transaction History

Intellectus Partners, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	BUY	$0.32 - $0.62 $3,584 - $6,944	11,200 Added 2.81%	410,385 $254,000
Q3 2023 Oct 25, 2023	SELL	$0.46 - $0.65 $9,018 - $12,743	-19,605 Reduced 4.68%	399,185 $191,000
Q2 2023 Jul 31, 2023	BUY	$0.57 - $1.08 $13,736 - $26,028	24,100 Added 6.11%	418,790 $251,000
Q1 2023 May 04, 2023	BUY	$0.66 - $1.29 $18,839 - $36,823	28,545 Added 7.8%	394,690 $296,000
Q4 2022 Feb 02, 2023	BUY	$1.1 - $2.45 $107,831 - $240,171	98,029 Added 36.56%	366,145 $454,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $23,912 - $40,504	12,200 Added 4.77%	268,116 $552,000
Q2 2022 Aug 12, 2022	BUY	$2.27 - $4.86 $43,211 - $92,514	19,036 Added 8.04%	255,916 $709,000
Q1 2022 May 16, 2022	BUY	$3.69 - $5.65 $48,966 - $74,975	13,270 Added 5.93%	236,880 $1.04 Million
Q4 2021 Feb 14, 2022	BUY	$5.37 - $7.07 $189,077 - $248,934	35,210 Added 18.69%	223,610 $1.23 Million
Q3 2021 Nov 16, 2021	BUY	$5.54 - $7.51 $178,942 - $242,573	32,300 Added 20.69%	188,400 $1.16 Million
Q2 2021 Aug 13, 2021	BUY	$7.78 - $11.4 $1.21 Million - $1.78 Million	156,100 New	156,100 $1.33 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Intellectus Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Intellectus Partners, LLC with notifications on news.